Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate

Executive Summary

• Red Light Holland Corp. has engaged Kala Bio’s Researgency.ai agentic AI platform to support clinical development of its psilocybin drug candidate PEX010.
• The partnership is part of Red Light’s broader strategy following its definitive arrangement to acquire Filament Health Corp., adding a large IP portfolio and advanced psychedelic pipeline.
• Red Light also retained Solidaire Investments Inc. as capital‑markets advisor for a one‑month term, paying a $20,000 fee.

Key Details

• Engagement Scope: Kala Bio will deploy purpose‑built AI research agents to assist with clinical planning, protocol optimization, and scenario modeling for PEX010 across multiple indications (alcohol use disorder, methamphetamine use disorder, treatment‑resistant depression, cancer‑related anxiety/depression, cannabis use disorder).
• Technology: Researgency.ai is an on‑premises, secure AI platform licensed worldwide by Kala Bio, designed to generate, simulate, and optimize study scenarios at scale.
• Acquisition Context: Red Light recently announced a definitive arrangement to acquire Filament Health Corp., gaining 76 issued patents across 15 families covering botanical psilocybin extraction, purification, stabilization, and delivery formulations.
• Clinical Status of PEX010: Supplied to >70 research sites worldwide; authorized by Health Canada and the U.S. FDA for clinical trials; has shown positive Phase 2 data in alcohol use disorder.
• Advisory Services: Solidaire Investments Inc., a Calgary‑based merchant bank, engaged to provide capital‑markets advisory and investor‑relations consulting; fee of $20,000 for an initial one‑month term.
• Management Comments:
• Todd Shapiro (CEO, Red Light) highlighted the AI platform as a “natural next step” to accelerate timelines and improve study designs.
• Ben Lightburn (CEO, Filament Health) emphasized strengthening clinical strategy evaluation via advanced analytics.
• Avi Minkowitz (CEO, Kala Bio) noted the platform’s fit for data‑intensive psychedelic development challenges.

Notable Quotes

• “By applying autonomous AI‑driven research capabilities to our clinical development planning, we believe we can accelerate timelines, strengthen study designs, and make smarter, faster decisions across PEX010's extensive clinical program.” – Todd Shapiro, CEO & Director, Red Light Holland
• “Red Light’s decision to deploy Researgency.ai underscores exactly the kind of high‑value, data‑intensive challenge our platform was built to address.” – Avi Minkowitz, CEO, Kala Bio